DBV Technologies Files FDA Application for Peanut Allergy Patch in Young Children
DBV Technologies has submitted a Biologics License Application to the U.S. FDA seeking approval of its Viaskin Peanut patch for children aged 4 to 7.
DBV Technologies announced Monday it has submitted a Biologics License Application to the U.S. Food and Drug Administration for its Viaskin Peanut patch, a skin-based immunotherapy device targeting peanut allergy in children between the ages of 4 and 7, the French biopharmaceutical company said from its headquarters in Châtillon, France.
The BLA submission marks a critical regulatory milestone for DBV, which has spent years developing epicutaneous immunotherapy — a needle-free approach that delivers peanut protein through a small adhesive patch worn on the skin. If cleared, Viaskin Peanut would offer a non-oral treatment option in a pediatric age group considered among the most vulnerable to severe allergic reactions.
Read more PwC: AI-Skilled Workers at Risk of Leaving as Training Falls →
Peanut allergy affects millions of children in the United States and remains one of the most common causes of fatal anaphylaxis in the pediatric population. Regulatory approval of a patch-based therapy could expand treatment access for families who face compliance challenges with existing oral immunotherapy regimens, which require daily ingestion of allergen doses under medical supervision.
The FDA review process for a BLA typically involves a standard or priority review period, with the agency assigning a target action date after accepting the application for filing. DBV has not disclosed whether it will seek priority review designation for this submission.
Continue reading at GlobeNewswire - Industry News on Financial Services.
